Find the latest Harmony Biosciences Holdings, Inc. (HRMY) stock quote, history, news and other vital information to help you with your stock trading and investing.

2025年3月11日 · HRMY | Complete Harmony Biosciences Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

4 天之前 · Get a real-time Harmony Biosciences Holdings, Inc. (HRMY) stock price with an overview of financials, statistics, forecasts, charts and more.

$Harmony (HRMY)$ 收购了私人控股的Epygenix Therapeutics，该公司专注于开发罕见癫痫疾病的治疗方法。 Harmony预付了3500万美元。 Epygenix有资格获得1.3亿美元的开发和监管里程碑，以及额外高达5.15亿美元的销售里程碑。 Epygenix最先进的候选药物是处于Dravet综合征2期的EPX-100，接近进... 查看全文. OYang 2024-04-30 20:10. #药闻简讯# $Harmony (HRMY)$ 收购了Epygenix Therapeutics，增加了晚期癫痫特许经营权。 查看全文. 牛唐 2023-09-08 17:23. 1 …

Get the latest Harmony Biosciences Holdings Inc (HRMY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

2025年3月11日 · See the latest Harmony Biosciences Holdings Inc Ordinary Shares stock price (HRMY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

6 天之前 · Harmony Biosciences Holdings serves patients in the United States. Stock analysis for Harmony Biosciences Holdings Inc (HRMY:NASDAQ GM) including stock price, stock chart, company news, key...

A high-level overview of Harmony Biosciences Holdings, Inc. (HRMY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors.

View the latest Harmony Biosciences Holdings Inc. (HRMY) stock price, news, historical charts, analyst ratings and financial information from WSJ.